CD44 expression in plexiform lesions of idiopathic pulmonary arterial hypertension

Pathology International

Volumn 62, Issue 4, 2012, Pages 219-225

  Ohta Ogo, Keiko ^a,b   Hao, Hiroyuki ^b,c   Ishibashi Ueda, Hatsue ^b   Hirota, Seiichi ^c   Nakamura, Kazufumi ^a   Ohe, Tohru ^a   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

CD44; Endothelial cell; Plexiform lesion; Pulmonary arterial hypertension

Indexed keywords

CD44V ANTIGEN; PROSTACYCLIN;

ADULT; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; HEART ATRIUM SEPTUM DEFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG LESION; LUNG PLEXIFORM LESION; MALE; MICROVASCULATURE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; ANTIGENS, CD44; BIOLOGICAL MARKERS; CHILD; ENDOTHELIUM, VASCULAR; FEMALE; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MICROVESSELS; MIDDLE AGED; PULMONARY ARTERY; T-LYMPHOCYTES;

EID: 84858997844     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2011.02779.x     Document Type: Article

References (31)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7.
2. Machado RD, Pauciulo MW, Thomson JR etal. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68: 92-102.
3. Newman JH, Wheeler L, Lane KB etal. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001; 345: 319-24.
4. Thomson JR, Machado RD, Pauciulo MW etal. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741-5.
5. Pietra GG, Capron F, Stewart S etal. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43: 25S-32S.
6. Pietra GG, Edwards WD, Kay JM etal. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-206.
7. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-85.
8. Tuder RM, Cool CD, Geraci MW etal. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-32.
9. Giaid A, Yanagisawa M, Langleben D etal. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-9.
10. Cool CD, Stewart JS, Werahera P etal. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999; 155: 411-9.
11. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101: 927-34.
12. Tuder RM, Chacon M, Alger L etal. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis. J Pathol 2001; 195: 367-74.
13. Humbert M, Monti G, Brenot F etal. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-31.
14. Itoh T, Nagaya N, Ishibashi-Ueda H etal. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 2006; 11: 158-63.
15. Balabanian K, Foussat A, Dorfmuller P etal. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1419-25.
16. Dorfmuller P, Zarka V, Durand-Gasselin I etal. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 534-9.
17. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-13.
18. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol 1999; 52: 189-96.
19. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 1997; 278: 672-5.
20. Estess P, DeGrendele HC, Pascual V, Siegelman MH. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J Clin Invest 1998; 102: 1173-82.
21. Trochon V, Mabilat C, Bertrand P etal. Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer 1996; 66: 664-8.
22. Griffioen AW, Coenen MJ, Damen CA etal. CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. Blood 1997; 90: 1150-59.
23. Simonneau G, Robbins IM, Beghetti M etal. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-54.
24. Krettek A, Sukhova GK, Schonbeck U, Libby P. Enhanced expression of CD44 variants in human atheroma and abdominal aortic aneurysm: Possible role for a feedback loop in endothelial cells. Am J Pathol 2004; 165: 1571-81.
25. DeGrendele HC, Kosfiszer M, Estess P, Siegelman MH. CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. J Immunol 1997; 159: 2549-53.
26. Siegelman MH, DeGrendele HC, Estess P. Activation and interaction of CD44 and hyaluronan in immunological systems. J Leukoc Biol 1999; 66: 315-21.
27. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997; 28: 434-42.
28. Aytekin M, Comhair SA, de la Motte C etal. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295: L789-99.
29. Papakonstantinou E, Kouri FM, Karakiulakis G, Klagas I, Eickelberg O. Increased hyaluronic acid content in idiopathic pulmonary arterial hypertension. Eur Respir J 2008; 32: 1504-12.
30. Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005; 112: 553-62.
31. Hagen M, Fagan K, Steudel W etal. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1473-9.